LNAILNAIHealthcare · Biotechnology

LNAI Stock Forecast: Lunai Bioworks, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$0.17
−30.08% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 27 of 100 as at 31 Oct 2026 — in the lower half.

Market cap
$829,677.00
Ticker Nerd rank
27/ 100
Median analyst target
—
Analysts covering
—
Revenue$21K
Operating income−$1.4M
Net income−$2.6M
Free cash flow−$1.0M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−64.9%
1M
−90.7%
YTD
−97.7%
1Y
−97.9%
From 52W high
−98.6%
From 52W low
0.0%
$0
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Lunai Bioworks, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
27/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
87
Issuance
63
Momentum
29
Accruals
25
Revisions
25
Volatility
25
Value
11
Quality
8

Growth (87): Sales and profits are climbing, and climbing faster than before.

Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LNAI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LNAI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$2$4$6$8$10$12Jan 26Apr 26Jul 26Oct 26LNAI

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

LNAI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LNAI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Lunai Bioworks, Inc. returned −97.9% against +13.1% for the S&P 500, dividends included.

LNAI vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26LNAIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LNAI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
16.0×

Cheaper than 9% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
100.0%

Higher than 99% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−54.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lunai Bioworks, Inc. has a market value of $830K and an enterprise value of $606K.

  • Revenue in the twelve months to 31 Mar 2026: $21K.

  • Net income over the same four quarters: −$128.3M, a −612568.1% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$5.3M.

  • Shares outstanding: 4.5M.

  • Lunai Bioworks, Inc. employs 12 people — $2K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

LNAI and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LNAILunai Bioworks, Inc.$829,677.0027
SLXNSilexion Therapeutics Corp.$830,400.0028
MTNBMatinas BioPharma Holdings, Inc.$890,700.0039
KPTIKaryopharm Therapeutics, Inc.$901,700.00—
BBLGBone Biologics Corp.$910,000.0037
GOVXGeoVax Labs, Inc.$985,500.0031
OGENOragenics, Inc.$680,800.0025

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Lunai Bioworks, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LNAI

How does Ticker Nerd's model rank LNAI?

As at 31 Oct 2026, Lunai Bioworks, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).

What is the LNAI stock forecast for 2030?

No analyst covering Lunai Bioworks, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LNAI are extrapolating price history, which says nothing about the business.

How has LNAI stock performed over the past year?

Lunai Bioworks, Inc. returned -97.9% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lunai Bioworks, Inc. do?

Lunai Bioworks Inc. is a pre-clinical biotechnology company focused on developing medicines, diagnostics, and biodefense solutions. The company works across cancer, infectious disease, and precision medicine through genetically modified cell and immune-therapy platforms, including allogeneic dendritic cell vaccine programs for solid tumors such as pancreatic and breast cancers.

Company

About Lunai Bioworks, Inc.

Lunai Bioworks Inc. is a pre-clinical biotechnology company focused on developing medicines, diagnostics, and biodefense solutions. The company works across cancer, infectious disease, and precision medicine through genetically modified cell and immune-therapy platforms, including allogeneic dendritic cell vaccine programs for solid tumors such as pancreatic and breast cancers. Its business also includes AI-enabled diagnostics and multi-omics analytics designed to support early cancer detection and recurrence monitoring by identifying individual biomarkers, including in asymptomatic patients. Through its operating segments, Lunai Bioworks combines computational biology, experimental biology, and data-driven platforms to advance therapeutic discovery and improve clinical decision-making. The company is headquartered in Los Angeles, California, and serves healthcare-related markets in the United States and the Netherlands.

CEO Mr. David H. Weinstein · 12 employees · United States · https://www.lunaibioworks.com